ABSTRACT
Background This study aimed to describe the clinical symptoms, the severity of the disease, and survival status of COVID-19 cancer patients, and comparing the results in the different cancer subtypes and stages among various ages/sexes and techniques of treatment.Method: In a descriptive-analytical study, the clinical status of 60 cancer patients with a history of Covid-19 over the past year from the covid-19 pandemic in Iran (Jan. 2020-Dec.2020) was assessed.Results Most of the patients (68%) were in the solid tumor categories. The mean age of the men was 52 ± 13 years, and women were 47 ± 13 years (P < 0.05). Most cases of COVID-19 positive in solid tumor were breast cancer (24.4%), colon cancer (22%), gastric cancer (9.8%), and in hematologic malignancy, lymphoma (31.6%), chronic lymphocytic leukemia (CLL) (31.6%), and acute leukemia (21.1%). There was a statistically significant difference between two categories of cancer in the clinical manifestations; the stage of cancer and survival status (P < 0.05).Conclusion Based on our results risk factors for Covid-19 disease progression, severe pulmonary involvement, and fatal complications in patients with malignancy require further evaluation based on tumor type, stage, age, sex, and treatment options.
Subject(s)
COVID-19ABSTRACT
Background: This study aimed to describe the clinical symptoms, the severity of the disease, and survival status of COVID-19 cancer patients, and comparing the results in the different cancer subtypes and stages among various ages/sexes and techniques of treatment.Method: In a descriptive-analytical study, the clinical status of 60 cancer patients with a history of Covid-19 over the past year from the covid-19 pandemic in Iran (Jan. 2020-Dec.2020) was assessed. Results: Most of the patients (68%) were in the solid tumor categories. The mean age of the men was 52 ± 13 years, and women were 47 ± 13 years (P<0.05). Most cases of COVID-19 positive in solid tumor were breast cancer (24.4%), colon cancer (22%), gastric cancer (9.8%), and in hematologic malignancy, lymphoma (31.6%), chronic lymphocytic leukemia (CLL) (31.6%), and acute leukemia (21.1%). There was a statistically significant difference between two categories of cancer in the clinical manifestations; the stage of cancer and survival status (P<0.05). Conclusion: Based on our results risk factors for Covid-19 disease progression, severe pulmonary involvement, and fatal complications in patients with malignancy require further evaluation based on tumor type, stage, age, sex, and treatment options.
Subject(s)
COVID-19ABSTRACT
Background: The aim of this study was investigation of COVID-19 disease and its outcome in cancer patients who needed treatment, in a 90-day period. Methods: Cancer patient who required treatment, were evaluated for potential COVID-19 infection in a 90-day period, starting from beginning of this epidemic in Iran, January, to April 19, 2020. For treatment of solid tumor patients, if they did not have symptoms related to COVID-19, just chest X-ray was requested. If they showed COVID-19 related symptoms, High Resolution CT scan of lungs was requested. For hematology cancer patients, PCR test for COVID-19 infection was requested as well. Protection measures were considered for personnel of oncology wards. Results: In this study, 279 patients were followed up in this 90-day period. No COVID-19 infection was observed in 92 cases of breast cancer, 72 cases of colon cancer, 14 cases of gastric cancer and 12 cases of pancreaticobiliary cancer .However, in 11 cases of lung cancer, 5 cases brain tumors and 12 cases ovarian cancer; 3 case of COVID-19 were observed. In the hematology cancers group, which included 14 cases of Hodgkin Lymphoma, 23 cases of lymphoproliferative disorder, 12 cases of acute leukemia and 12 cases of multiple myeloma; three of COVID-19 were observed. Conclusion: Patients with cancer who need treatment can be treated by taking some measures. These measures include observing individual and collective protection principles in patients and health-care personnel, increasing patients awareness particularly about self-care behavior, performing a COVID-19 test, and taking a chest X ray, before the treatment starts